Video content material above is prompted by the next questions:
- Focus on the info that was offered on the ASCO 2024 on mixture use amivantamab and lazertinib within the CHRYSALIS-2 research for sufferers who have been treatment-naïve or had ≤ 2 prior traces.
- Based mostly on this research, how do you assume amivantamab plus lazertinib compares with different present therapies used for EGFR mutations in NSCLC?
- How would possibly the security information from this research influence remedy selections and administration methods in medical apply?
